Australia's largest stock trading and investment forum Australia's #1 stock forum

SE1

Click for more information

0.00%

0.2¢ sensera limited

Another thing that stood out to me was that Ralph seemed very...

First 10 Last

Share
Profile

Follow
Osctheo

88 Posts.

10

01/02/19

15:56

Post #: 37302193
Share

Originally posted by Osctheo ↑

Hi all,

Here is my update on the investor call.

I woke up early this morning to attend the conference call and was also happy to get some answers to the questions which I sent in yesterday. One thing I can assure everyone here - the quality and positiveness of the call is in NO WAY reflected by the direction of our SP currently. I'm sure when the recorded call is posted, everyone here would agree. However, make no mistake, the SP drop is hurting me but things will change in time.

The comments by Dave was obviously going to be the most important given the cash position. Dave our CFO confirmed that in excess of $1.1 million was received the first 2 weeks alone of the current quarter. It was unfortunate that the receipt of these cash payments were received post the 31 Dec. Dave advised that shareholders should expect a record cash receipt quarter well in excess of the highest amount previously receipt in any given quarter in Sensera's history (i.e. well in excess of $2.5 million). Lets just take the baseline of $2.5 million and that would give us $3m to work with. However, as previously mentioned, the cash receipts will be WELL IN EXCESS of $2.5 million. They are very cautious about diluting shareholders and spoke about a plan which they have to inject capital without dilution and Timelio facility was only the first of the steps in this plan.

Ralph mentioned on the call that this quarter will see many ramp ups in revenue. Firstly, we only started to ship to Zoetis during the last quarter so this quarter will see a full quarter of demand. Secondly, and this was one of my questions which I posted to management yesterday, ABIOMED - we are only just starting to see commercial revenues coming through but they are only really starting to go full throttle at marketing the Impella CP with SmartAssist this quarter and will be much higher revenues from Abiomed in subsequent quarters. No official stats as yet from Abiomed as their marketing campaign is only just starting. They are very confident that they will be running a profitable business by the end of this FY and the financials don't lie - they are definitely making significant progress towards this milestone.

We are also starting to migrate a lot of customers to production in the MEMs space. This is a rapidly growing part of Sensera's business and Ralph actually stated that he believes that the MEMs business will be profitable moving into the 4th quarter. I.e. at least breakeven by this quarter. This is a tremendous achievement in my opinion. A lot of development in the MEMs space which will also fill the pipeline for FY20.

Overall, I don't think Sensera has been in better hands and definitely has not been in a better position then the position which they are currently in. Yes, the share price is a stinker but the fundamentals of the business have only improved.

Will report more when I have re-listened to the entire conference call - can't remember every detail of it.

GLTH,

Chart

Expand

Another thing that stood out to me was that Ralph seemed very excited about the MEMs space. Don’t quote me on this (until you have heard the conference call for yourself) but he did mention something along the lines that Sensera is finally starting to be a key player in the MEMs industry, particularly in the medtech space.

Previously, I think the MEMs business was well behind and the cash drainer but it’s come from no where to probably be the first side of the business to reach break even - that’s crazy in itself.

Microfluidics is the key I reckon - this side of the business could be the company maker. Being integrated into the King of heart pumps is massive and I’m sure is opening doors all over the industry.

SE1 Price at posting: 12.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

2 Great analysis

Reply

Top Stories

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

There are more pages in this discussion • 2 more messages in this thread...

First 10 Last

Add SE1 (ASX) to my watchlist